Initiation of antiretroviral therapy at high CD4+ cell counts is associated with positive treatment outcomes

AIDS

Volumn 29, Issue 14, 2015, Pages 1871-1882

  Lima, Viviane D ^a   Reuter, Anja ^a   Harrigan, P Richard ^a   Lourenço, Lillian ^a   Chau, William ^a   Hull, Mark ^a   Mackenzie, Lauren ^a,b   Guillemi, Silvia ^a   Hogg, Robert S ^a,c   Barrios, Rolando ^a   Montaner, Julio S G ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c SIMON FRASER UNIVERSITY   (Canada)

Author keywords

Adherence; AIDS defining illness; Antiretroviral therapy; CD4+ cell count; Combination antiretroviral therapy; Drug resistance; Loss to follow up; Mortality; Viral load; Viral suppression

Indexed keywords

ATAZANAVIR; EFAVIRENZ; LOPINAVIR; NEVIRAPINE; ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MORTALITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VIRUS INHIBITION; VIRUS LOAD; ANTIVIRAL RESISTANCE; HIV INFECTIONS; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; SURVIVAL ANALYSIS;

ADULT; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84944072826     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000790     Document Type: Article

References (53)

1. The Joint United Nations Programme on HIV/AIDS. HIV estimates with uncertainty bounds. http://www.unaids.org/en/resources/documents/2014/HIV-estimates-with-undertainty-bounds-1990-2013. 2014.
2. Molina JM, Cahn P, Grinsztejn B, Lazzarin A, Mills A, Saag M, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet 2011;378:238-246.
3. Nelson M, Amaya G, Clumeck N, Arns Da Cunha C, Jayaweera D, Junod P, et al. Efficacy and safety of rilpivirine in treatmentnaive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials. J Antimicrob Chemother 2012;67:2020-2028.
4. Raffi F, Jaeger H, Quiros-Roldan E, Albrecht H, Belonosova E, Gatell JM, et al. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study):96 week results from a randomised, doubleblind, non-inferiority trial. Lancet Infect Dis 2013;13:927-935.
5. Raffi F, Rachlis A, Brinson C, Arasteh K, Gorgolas M, Brennan C, et al. Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials. AIDS 2015;29:167-174.
6. Rockstroh JK, DeJesus E, Lennox JL, Yazdanpanah Y, Saag MS, Wan H, et al. Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK. J Acquir Immune Defic Syndr 2013;63:77-85.
7. Rockstroh JK, Lennox JL, Dejesus E, Saag MS, Lazzarin A, Wan H, et al. Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. Clin Infect Dis 2011;53:807-816.
8. Sax PE, Tierney C, Collier AC, Daar ES, Mollan K, Budhathoki C, et al. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. J Infect Dis 2011;204:1191-1201.
9. Okulicz JF, Le TD, Agan BK, Camargo JF, Landrum ML, Wright E, et al. Influence of the timing of antiretroviral therapy on the potential for normalization of immune status in human immunodeficiency virus 1-infected individuals. JAMA Intern Med 2015;175:88-99.
10. Thornhill J, Inshaw J, Oomeer S, Kaleebu P, Cooper D, Ramjee G, et al. Enhanced normalisation of CD4/CD8 ratio with early antiretroviral therapy in primary HIV infection. J Int AIDS Soc 2014;17:19480.
11. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-860.
12. Hoffmann CJ, Gallant JE. Rationale and evidence for human immunodeficiency virus treatment as prevention at the individual and population levels. Infect Dis Clin North Am 2014;28:549-561.
13. Montaner JS, Hogg R, Wood E, Kerr T, Tyndall M, Levy AR, et al. The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet 2006;368:531-536.
14. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009;373:48-57.
15. Lima VD, Johnston K, Hogg RS, Levy AR, Harrigan PR, Anema A, et al. Expanded accessto highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic. J Infect Dis 2008;198:59-67.
16. The Joint United Nations Programme on HIV/AIDS. 90-90-90: an ambitious treatment target to help end the AIDS epidemic. http://www.unaids.org/en/resources/documents/2014/90-90-90. 2014.
17. Gunthard HF, Aberg JA, Eron JJ, Hoy JF, Telenti A, Benson CA, et al. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. JAMA 2014;312:410-425.
18. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011;365:493-505.
19. HIV-CAUSAL Collaboration. Cain LE, Logan R, Robins JM, Sterne JA, Sabin C, Bansi L, et al. When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study. Ann Intern Med 2011;154:509-515.
20. Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, et al. Effect of early versus deferred antiretroviral therapy for HIV onsurvival. NEngl JMed 2009;360:1815-1826.
21. Samji H, Cescon A, Hogg RS, Modur SP, Althoff KN, Buchacz K, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One 2013;8:e81355.
22. Strategies for Management of Antiretroviral Therapy Study G. Emery S, Neuhaus JA, Phillips AN, Babiker A, Cohen CJ, Gatell JM, et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis 2008;197:1133-1144.
23. When To Start C, Sterne JA, May M, Costagliola D, De Wolf F, Phillips AN, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 2009;373:1352-1363.
24. Writing Committee for the CC. Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters. Arch Intern Med 2011;171:1560-1569.
25. Berheto TM, Haile DB, Mohammed S. Predictors of loss to follow-up in patients living with HIV/AIDS after initiation of antiretroviral therapy. N Am J Med Sci 2014;6:453-459.
26. Clouse K, Pettifor A, Maskew M, Bassett J, Van Rie A, Gay C, et al. Initiating antiretroviral therapy when presenting with higher CD4 cell counts results in reduced loss to follow-up in a resource-limited setting. AIDS 2013;27:645-650.
27. Kranzer K, Lewis JJ, Ford N, Zeinecker J, Orrell C, Lawn SD, et al. Treatment interruption in a primary care antiretroviral therapy program in South Africa: cohort analysis of trends and risk factors. J Acquir Immune Defic Syndr 2010;55:e17-e23.
28. Onoka CA, Uzochukwu BS, Onwujekwe OE, Chukwuka C, Ilozumba J, Onyedum C, et al. Retention and loss to follow-up in antiretroviral treatment programmes in southeast Nigeria. Pathog Glob Health 2012;106:46-54.
29. Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, et al. Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. JAMA 1996;276:146-154.
30. Geretti AM, Smith C, Haberl A, Garcia-Diaz A, Nebbia G, Johnson M, et al. Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy. Antivir Ther 2008;13:927-936.
31. Uy J, Armon C, Buchacz K, Wood K, Brooks JT, HOPS Investigators. Initiation of HAART at higher CD4 cell counts is associated with a lower frequency of antiretroviral drug resistance mutations at virologic failure. J Acquir Immune Defic Syndr 2009;51:450-453.
32. Phillips AN, Dunn D, Sabin C, Pozniak A, Matthias R, Geretti AM, et al. Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS 2005;19:487-494.
33. Phillips AN, Leen C, Wilson A, Anderson J, Dunn D, Schwenk A, et al. Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study. Lancet 2007;370:1923-1928.
34. Lodi S, Phillips A, Fidler S, Hawkins D, Gilson R, McLean K, et al. Role of HIV infection duration and CD4 cell level at initiation of combination anti-retroviral therapy on risk of failure. PLoS One 2013;8:e75608.
35. Laprise C, De Pokomandy A, Baril JG, Dufresne S, Trottier H. Virologic failure following persistent low-level viremia in a cohort of HIV-positive patients: results from 12 years of observation. Clin Infect Dis 2013;57:1489-1496.
36. Lapadula G, Cozzi-Lepri A, Marchetti G, Antinori A, Chiodera A, Nicastri E, et al. Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment. AIDS 2013;27:769-779.
37. British Columbia Centre for Excellence in HIV/AIDS. Therapeutic guidelines antiretroviral (ARV) treatment of adult HIV infection. http://www.cfenet.ubc.ca/sites/default/files/uploads/Therapeutic%20Guidelines%202013-Feb-final.pdf. [Accessed 20 January 2015]
38. Sun R, Ku J, Jayakar H, Kuo JC, Brambilla D, Herman S, et al. Ultrasensitive reverse transcription-PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 1998;36:2964-2969.
39. Schumacher W, Frick E, Kauselmann M, Maier-Hoyle V, Van Der Vliet R, Babiel R. Fully automated quantification of human immunodeficiency virus (HIV) type 1 RNAin human plasma by the COBAS AmpliPrep/COBAS TaqMan system. J Clin Virol 2007;38:304-312.
40. Brumme CJ, Swenson LC, Wynhoven B, Yip B, Skinner S, Lima VD, et al. Technical and regulatory shortcomings of the Taq-Man version 1 HIV viral load assay. PLoS One 2012;7:e43882.
41. De Bel A, Marissens D, Debaisieux L, Liesnard C, Van Den Wijngaert S, Lauwers S, et al. Correction of underquantification of human immunodeficiency virus type 1 load with the second version of the Roche Cobas AmpliPrep/Cobas TaqMan assay. J Clin Microbiol 2010;48:1337-1342.
42. Gonzalez-Serna A, Min JE, Woods C, Chan D, Lima VD, Montaner JS, et al. Performance of HIV-1 drug resistance testing at low-level viremia and its ability to predict future virologic outcomes and viral evolution in treatment-naive individuals. Clin Infect Dis 2014;58:1165-1173.
43. Lima VD, Bangsberg DR, Harrigan PR, Deeks SG, Yip B, Hogg RS, et al. Risk of viral failure declines with duration of suppression on highly active antiretroviral therapy irrespective of adherence level. J Acquir Immune Defic Syndr 2010;55:460-465.
44. Fitzmaurice G, Laird N, Ware J. Applied longitudinal analysis. Hoboken N: John Wiley & Sons; 2004.
45. Wensing AM, Calvez V, Gunthard HF, Johnson VA, Paredes R, Pillay D, et al. 2014 Update of the drug resistance mutations in HIV-1. Top Antivir Med 2014;22:642-650.
46. McDonald JH. Handbook of biological statistics. 3rd ed. Baltimore, Maryland: Sparky House Publishing; 2014.
47. Nachega JB, Uthman OA, Del Rio C, Mugavero MJ, Rees H, Mills EJ. Addressing the Achilles' heel in the HIV care continuum for the success of a test-and-treat strategy to achieve an AIDS-free generation. Clin Infect Dis 2014;59 Suppl 1:S21-S27.
48. Katz IT, Essien T, Marinda ET, Gray GE, Bangsberg DR, Martinson NA, et al. Antiretroviral therapy refusal among newly diagnosed HIV-infected adults. AIDS 2011;25:2177-2181.
49. Lima VD, Harrigan R, Bangsberg DR, Hogg RS, Gross R, Yip B, et al. The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time. J Acquir Immune Defic Syndr 2009;50:529-536.
50. Lesko CR, Cole SR, Zinski A, Poole C, Mugavero MJ. A systematic review and meta-regression of temporal trends in adult CD4 (R) cell count at presentation to HIV care, 1992-2011. Clin Infect Dis 2013;57:1027-1037.
51. Donnell DJ, Hall HI, Gamble T, Beauchamp G, Griffin AB, Torian LV, et al. Use of HIV case surveillance system to design and evaluate site-randomized interventions in an HIV prevention study: HPTN 065. Open AIDS J 2012;6:122-130.
52. Cori A, Ayles H, Beyers N, Schaap A, Floyd S, Sabapathy K, et al. HPTN 071 (PopART): a cluster-randomized trial of the population impact of an HIV combination prevention intervention including universal testing and treatment: mathematical model. PLoS One 2014;9:e84511.
53. Iwuji CC, Orne-Gliemann J, Tanser F, Boyer S, Lessells RJ, Lert F, et al. Evaluation of the impact of immediate versus WHO recommendations-guided antiretroviral therapy initiation on HIV incidence: the ANRS 12249 TasP (Treatment as Prevention) trial in Hlabisa sub-district, KwaZulu-Natal, South Africa: study protocol for a cluster randomised controlled trial. Trials 2013;14:230.